Davita - White Oak Home Dialysis is a medicare approved dialysis facility center in Cincinnati, Ohio and it has 4 dialysis stations. It is located in Hamilton county at 5520 Cheviot Road, Suite B, Cincinnati, OH, 45247. You can reach out to the office of Davita - White Oak Home Dialysis at (513) 385-3580. This dialysis clinic is managed and/or owned by Davita. Davita - White Oak Home Dialysis has the following ownership type - Profit. It was first certified by medicare in August, 2006. The medicare id for this facility is 362687 and it accepts patients under medicare ESRD program.
Name | Davita - White Oak Home Dialysis |
---|---|
Location | 5520 Cheviot Road, Suite B, Cincinnati, Ohio |
No. of Dialysis Stations | 4 |
Medicare ID | 362687 |
Managed By | Davita |
Ownership Type | Profit |
Late Shifts | No |
5520 Cheviot Road, Suite B, Cincinnati, Ohio, 45247 | |
(513) 385-3580 | |
News Archive
Human Genome Sciences, Inc. announced today a license agreement with DakoCytomation A/S (Glostrup, Denmark), under which DakoCytomation has acquired exclusive worldwide rights to develop and commercialize pharmacogenomic diagnostic tests in the field of oncology based on the TRAIL Receptor-1 (TRAIL-R1) and TRAIL Receptor-2 (TRAIL-R2) proteins.
Almost entirely along party-lines, the House voted to repeal a provision of the health law that establishes a trust fund to support prevention and public health activities. Opponents of the trust fund said it was a "slush fund" for the HHS secretary, but the White House responded by threatening a veto.
The UN's criteria for individual rights and fairness form the basis for a newly-published critique of COVID-19 contact-tracing app guidelines for Europe, and of apps already being used by millions in Austria and Singapore.
NPR interviewed two leading health care experts - Uwe Reinhardt, a Princeton professor, and Gail Wilensky, an economist who ran Medicare under the first President Bush - to shed light on the current plight of pending health care overhaul.
Amgen and GlaxoSmithKline (GSK) today announced a collaboration in which the companies will share commercialization of Amgen's monoclonal antibody denosumab for postmenopausal osteoporosis (PMO) in Europe, Australia, New Zealand and Mexico once the product is approved in these countries.
› Verified 7 days ago
NPI Number | 1598784506 |
Organization Name | White Oak Home Training Dialysis |
Doing Business As | Ohio River Dialysis Llc |
Address | 5520 Cheviot Rd Ste B Cincinnati, Ohio, 45247 |
Phone Number | (513) 385-3580 |
News Archive
Human Genome Sciences, Inc. announced today a license agreement with DakoCytomation A/S (Glostrup, Denmark), under which DakoCytomation has acquired exclusive worldwide rights to develop and commercialize pharmacogenomic diagnostic tests in the field of oncology based on the TRAIL Receptor-1 (TRAIL-R1) and TRAIL Receptor-2 (TRAIL-R2) proteins.
Almost entirely along party-lines, the House voted to repeal a provision of the health law that establishes a trust fund to support prevention and public health activities. Opponents of the trust fund said it was a "slush fund" for the HHS secretary, but the White House responded by threatening a veto.
The UN's criteria for individual rights and fairness form the basis for a newly-published critique of COVID-19 contact-tracing app guidelines for Europe, and of apps already being used by millions in Austria and Singapore.
NPR interviewed two leading health care experts - Uwe Reinhardt, a Princeton professor, and Gail Wilensky, an economist who ran Medicare under the first President Bush - to shed light on the current plight of pending health care overhaul.
Amgen and GlaxoSmithKline (GSK) today announced a collaboration in which the companies will share commercialization of Amgen's monoclonal antibody denosumab for postmenopausal osteoporosis (PMO) in Europe, Australia, New Zealand and Mexico once the product is approved in these countries.
› Verified 7 days ago
Dialysis patients with Hemoglobin data | 37 |
Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 19 |
Medicare patients who had average hemoglobin (hgb) greater than 12 g/dL | 3 |
News Archive
Human Genome Sciences, Inc. announced today a license agreement with DakoCytomation A/S (Glostrup, Denmark), under which DakoCytomation has acquired exclusive worldwide rights to develop and commercialize pharmacogenomic diagnostic tests in the field of oncology based on the TRAIL Receptor-1 (TRAIL-R1) and TRAIL Receptor-2 (TRAIL-R2) proteins.
Almost entirely along party-lines, the House voted to repeal a provision of the health law that establishes a trust fund to support prevention and public health activities. Opponents of the trust fund said it was a "slush fund" for the HHS secretary, but the White House responded by threatening a veto.
The UN's criteria for individual rights and fairness form the basis for a newly-published critique of COVID-19 contact-tracing app guidelines for Europe, and of apps already being used by millions in Austria and Singapore.
NPR interviewed two leading health care experts - Uwe Reinhardt, a Princeton professor, and Gail Wilensky, an economist who ran Medicare under the first President Bush - to shed light on the current plight of pending health care overhaul.
Amgen and GlaxoSmithKline (GSK) today announced a collaboration in which the companies will share commercialization of Amgen's monoclonal antibody denosumab for postmenopausal osteoporosis (PMO) in Europe, Australia, New Zealand and Mexico once the product is approved in these countries.
› Verified 7 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
Adult patients getting regular hemodialysis at the center | 6 |
Adult patient months included in Kt/V greater than or equal to 1.2 | 53 |
Percentage of adult patients getting regular hemodialysis at the center | |
Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Human Genome Sciences, Inc. announced today a license agreement with DakoCytomation A/S (Glostrup, Denmark), under which DakoCytomation has acquired exclusive worldwide rights to develop and commercialize pharmacogenomic diagnostic tests in the field of oncology based on the TRAIL Receptor-1 (TRAIL-R1) and TRAIL Receptor-2 (TRAIL-R2) proteins.
Almost entirely along party-lines, the House voted to repeal a provision of the health law that establishes a trust fund to support prevention and public health activities. Opponents of the trust fund said it was a "slush fund" for the HHS secretary, but the White House responded by threatening a veto.
The UN's criteria for individual rights and fairness form the basis for a newly-published critique of COVID-19 contact-tracing app guidelines for Europe, and of apps already being used by millions in Austria and Singapore.
NPR interviewed two leading health care experts - Uwe Reinhardt, a Princeton professor, and Gail Wilensky, an economist who ran Medicare under the first President Bush - to shed light on the current plight of pending health care overhaul.
Amgen and GlaxoSmithKline (GSK) today announced a collaboration in which the companies will share commercialization of Amgen's monoclonal antibody denosumab for postmenopausal osteoporosis (PMO) in Europe, Australia, New Zealand and Mexico once the product is approved in these countries.
› Verified 7 days ago
Adult patients getting regular peritoneal dialysis at the center | 85 |
Adult patient months included in Kt/V greater than or equal to 1.7 | 783 |
Percentage of adult patients getting regular peritoneal dialysis at the center | 97 |
Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
Human Genome Sciences, Inc. announced today a license agreement with DakoCytomation A/S (Glostrup, Denmark), under which DakoCytomation has acquired exclusive worldwide rights to develop and commercialize pharmacogenomic diagnostic tests in the field of oncology based on the TRAIL Receptor-1 (TRAIL-R1) and TRAIL Receptor-2 (TRAIL-R2) proteins.
Almost entirely along party-lines, the House voted to repeal a provision of the health law that establishes a trust fund to support prevention and public health activities. Opponents of the trust fund said it was a "slush fund" for the HHS secretary, but the White House responded by threatening a veto.
The UN's criteria for individual rights and fairness form the basis for a newly-published critique of COVID-19 contact-tracing app guidelines for Europe, and of apps already being used by millions in Austria and Singapore.
NPR interviewed two leading health care experts - Uwe Reinhardt, a Princeton professor, and Gail Wilensky, an economist who ran Medicare under the first President Bush - to shed light on the current plight of pending health care overhaul.
Amgen and GlaxoSmithKline (GSK) today announced a collaboration in which the companies will share commercialization of Amgen's monoclonal antibody denosumab for postmenopausal osteoporosis (PMO) in Europe, Australia, New Zealand and Mexico once the product is approved in these countries.
› Verified 7 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Davita - White Oak Home Dialysis with elevated calcium levels.
Patients with hypercalcemia | 108 |
Hypercalcemia patient months | 1000 |
Patients with Serumphosphor | 118 |
Patients with Serumphosphor less than 3.5 mg/dL | 7 |
Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 34 |
Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 34 |
Patients with Serumphosphor from 5.6 to 7 mg/dL | 17 |
Patients with Serumphosphor greater than 7 mg/dL | 7 |
News Archive
Human Genome Sciences, Inc. announced today a license agreement with DakoCytomation A/S (Glostrup, Denmark), under which DakoCytomation has acquired exclusive worldwide rights to develop and commercialize pharmacogenomic diagnostic tests in the field of oncology based on the TRAIL Receptor-1 (TRAIL-R1) and TRAIL Receptor-2 (TRAIL-R2) proteins.
Almost entirely along party-lines, the House voted to repeal a provision of the health law that establishes a trust fund to support prevention and public health activities. Opponents of the trust fund said it was a "slush fund" for the HHS secretary, but the White House responded by threatening a veto.
The UN's criteria for individual rights and fairness form the basis for a newly-published critique of COVID-19 contact-tracing app guidelines for Europe, and of apps already being used by millions in Austria and Singapore.
NPR interviewed two leading health care experts - Uwe Reinhardt, a Princeton professor, and Gail Wilensky, an economist who ran Medicare under the first President Bush - to shed light on the current plight of pending health care overhaul.
Amgen and GlaxoSmithKline (GSK) today announced a collaboration in which the companies will share commercialization of Amgen's monoclonal antibody denosumab for postmenopausal osteoporosis (PMO) in Europe, Australia, New Zealand and Mexico once the product is approved in these countries.
› Verified 7 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
Patients included in arterial venous fistula and catheter summaries | 16 |
Patient months included in arterial venous fistula and catheter summaries | 172 |
Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 80 |
Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 7 |
News Archive
Human Genome Sciences, Inc. announced today a license agreement with DakoCytomation A/S (Glostrup, Denmark), under which DakoCytomation has acquired exclusive worldwide rights to develop and commercialize pharmacogenomic diagnostic tests in the field of oncology based on the TRAIL Receptor-1 (TRAIL-R1) and TRAIL Receptor-2 (TRAIL-R2) proteins.
Almost entirely along party-lines, the House voted to repeal a provision of the health law that establishes a trust fund to support prevention and public health activities. Opponents of the trust fund said it was a "slush fund" for the HHS secretary, but the White House responded by threatening a veto.
The UN's criteria for individual rights and fairness form the basis for a newly-published critique of COVID-19 contact-tracing app guidelines for Europe, and of apps already being used by millions in Austria and Singapore.
NPR interviewed two leading health care experts - Uwe Reinhardt, a Princeton professor, and Gail Wilensky, an economist who ran Medicare under the first President Bush - to shed light on the current plight of pending health care overhaul.
Amgen and GlaxoSmithKline (GSK) today announced a collaboration in which the companies will share commercialization of Amgen's monoclonal antibody denosumab for postmenopausal osteoporosis (PMO) in Europe, Australia, New Zealand and Mexico once the product is approved in these countries.
› Verified 7 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
Patients in facility's Hospitalization Summary | 81 |
Hospitalization Rate in facility | 150.5 (As Expected) |
Hospitalization Rate: Upper Confidence Limit | 268.4 |
Hospitalization Rate: Lower Confidence Limit | 87 |
News Archive
Human Genome Sciences, Inc. announced today a license agreement with DakoCytomation A/S (Glostrup, Denmark), under which DakoCytomation has acquired exclusive worldwide rights to develop and commercialize pharmacogenomic diagnostic tests in the field of oncology based on the TRAIL Receptor-1 (TRAIL-R1) and TRAIL Receptor-2 (TRAIL-R2) proteins.
Almost entirely along party-lines, the House voted to repeal a provision of the health law that establishes a trust fund to support prevention and public health activities. Opponents of the trust fund said it was a "slush fund" for the HHS secretary, but the White House responded by threatening a veto.
The UN's criteria for individual rights and fairness form the basis for a newly-published critique of COVID-19 contact-tracing app guidelines for Europe, and of apps already being used by millions in Austria and Singapore.
NPR interviewed two leading health care experts - Uwe Reinhardt, a Princeton professor, and Gail Wilensky, an economist who ran Medicare under the first President Bush - to shed light on the current plight of pending health care overhaul.
Amgen and GlaxoSmithKline (GSK) today announced a collaboration in which the companies will share commercialization of Amgen's monoclonal antibody denosumab for postmenopausal osteoporosis (PMO) in Europe, Australia, New Zealand and Mexico once the product is approved in these countries.
› Verified 7 days ago
The rate of readmission show you whether patients who were being treated regularly at Davita - White Oak Home Dialysis were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
Readmission Rate in facility | 18.8 (As Expected) |
Readmission Rate: Upper Confidence Limit | 30.9 |
Readmission Rate: Lower Confidence Limit | 10.1 |
News Archive
Human Genome Sciences, Inc. announced today a license agreement with DakoCytomation A/S (Glostrup, Denmark), under which DakoCytomation has acquired exclusive worldwide rights to develop and commercialize pharmacogenomic diagnostic tests in the field of oncology based on the TRAIL Receptor-1 (TRAIL-R1) and TRAIL Receptor-2 (TRAIL-R2) proteins.
Almost entirely along party-lines, the House voted to repeal a provision of the health law that establishes a trust fund to support prevention and public health activities. Opponents of the trust fund said it was a "slush fund" for the HHS secretary, but the White House responded by threatening a veto.
The UN's criteria for individual rights and fairness form the basis for a newly-published critique of COVID-19 contact-tracing app guidelines for Europe, and of apps already being used by millions in Austria and Singapore.
NPR interviewed two leading health care experts - Uwe Reinhardt, a Princeton professor, and Gail Wilensky, an economist who ran Medicare under the first President Bush - to shed light on the current plight of pending health care overhaul.
Amgen and GlaxoSmithKline (GSK) today announced a collaboration in which the companies will share commercialization of Amgen's monoclonal antibody denosumab for postmenopausal osteoporosis (PMO) in Europe, Australia, New Zealand and Mexico once the product is approved in these countries.
› Verified 7 days ago